TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Sponsor: Medtronic Cardiovascular · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1056 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT03242642 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03242642 Rescue Dossier →